Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
BIOLOGICAL TREATMENT OF NSCLC - THE NEED FOR CONCLUSIVE STUDIES
Autore:
JASSEM J;
Indirizzi:
MED UNIV GDANSK,DEPT RADIOTHERAPY & ONCOL,UL DEBINKI 7 PL-80211 GDANSK POLAND
Titolo Testata:
Chest
fascicolo: 5, volume: 109, anno: 1996, supplemento:, S
pagine: 119 - 124
SICI:
0012-3692(1996)109:5<119:BTON-T>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
CELL LUNG-CANCER; RECOMBINANT ALPHA-INTERFERON; PHASE-II; BRONCHOGENIC-CARCINOMA; INTRAPLEURAL BCG; ADJUVANT IMMUNOTHERAPY; THORACIC IRRADIATION; BRONCHIAL-CARCINOMA; RANDOMIZED TRIAL; FOLLOW-UP;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
62
Recensione:
Indirizzi per estratti:
Citazione:
J. Jassem, "BIOLOGICAL TREATMENT OF NSCLC - THE NEED FOR CONCLUSIVE STUDIES", Chest, 109(5), 1996, pp. 119-124

Abstract

Despite extensive investigation, biological treatments for non-small cell lung cancer (NSCLC) remain largely undeveloped. The lack of satisfactory models has frequently led to inadequate phase II studies and to small and inconclusive phase III trials, Nonuniformity of trials hasprevented clearer er conclusions from being reached by meta-analysis. In general, immunotherapy has failed to fulfill expectations for clinical usefulness. The benefit with this approach, if any, seems to be marginal, but it is not clear whether this is a result of lack of activity or faulty clinical testing. The future of biological agents in cancer treatment lies in ongoing advances in molecular biology, for example in making tumors more immunogenic. Another avenue of further clinical research includes novel forms of therapy with monoclonal antibodies, Adequate models for testing and appropriate clinical trial settings could clarify the role of biological agents in NSCLC.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 21:48:12